• BHPF as a GPER1 Inhibitor: Mechanistic Insights in Neuroblas

  2026-07-16

  This study uncovers how fluorene-9-bisphenol (BHPF), a BPA substitute, directly binds and inhibits the G protein-coupled estrogen receptor 1 (GPER1), altering apoptosis pathways in human neuroblastoma cells. The research combines molecular dynamics, mutagenesis, and functional assays to reveal BHPF’s unique interference with GPER1 signaling, distinguishing it from both BPA and classical estrogen response modulators.

• Hypoxia and Immunometabolism: Mechanisms in Tumor Progressio

  2026-07-16

  This review dissects how hypoxia and metabolic adaptation drive immune suppression in the tumor microenvironment. By detailing molecular mechanisms and the competitive dynamics for glucose, it highlights strategic opportunities for metabolism-targeted cancer therapies.

• Optimizing Fluorescent Protein Expression with mCherry mRNA

  2026-07-15

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) elevates reporter gene workflows by enhancing mRNA stability, translation, and immune evasion. Discover how this next-gen red fluorescent protein mRNA enables high-fidelity cellular imaging and reliable quantitative assays, even in challenging systems.

• Octyl-α-ketoglutarate: A Strategic Tool for Hypoxia and IDH

  2026-07-15

  Explore how Octyl-α-ketoglutarate empowers translational researchers to dissect the interplay between metabolic reprogramming, HIF-1α regulation, and cancer progression—going beyond product pages with mechanistic context, protocol guidance, and translational insights.

• HotStart™ 2X Green qPCR Master Mix in Translational Oncology

  2026-07-14

  Discover how HotStart™ 2X Green qPCR Master Mix empowers high-precision SYBR Green qPCR for gene expression analysis in oncology. This article uniquely integrates advanced assay design with recent findings on sunitinib resistance and ferroptosis.

• Abiraterone Acetate: CYP17 Inhibitor Workflows in 3D Prostat

  2026-07-14

  Abiraterone acetate empowers prostate cancer researchers with a potent, selective CYP17 inhibitor ideal for dissecting androgen signaling in both 2D and cutting-edge 3D spheroid models. This article delivers stepwise experimental workflows, optimization strategies, and troubleshooting tips to unlock reproducible, translational insights in castration-resistant prostate cancer research.

• Etomoxir in Fatty Acid Oxidation Pathway Research Protocols

  2026-07-13

  Etomoxir empowers immunometabolic and metabolic disorder research by enabling precise inhibition of CPT-1 and DGAT, facilitating reproducible modulation of fatty acid oxidation pathways. This article unpacks optimized workflows, troubleshooting insights, and the transformative impact of standardized whole-blood metabolic assays.

• MOG (35-55) Peptide: Driving Precision in Autoimmune Encepha

  2026-07-13

  MOG (35-55) Peptide empowers researchers to model multiple sclerosis with unparalleled reproducibility, supporting mechanistic and therapeutic studies in neuroinflammation. Recent advances, including targeted PARP7 inhibition, unlock novel assay readouts and disease-modifying strategies in EAE workflows.

• Wnt and BMP Patterning of Hemichordate Neuroectoderm: Insigh

  2026-07-12

  This study delineates how Wnt and BMP signaling pathways establish the anterior neuroectoderm (ANE) in the indirect-developing hemichordate Ptychodera flava. By mapping gene expression and pathway function during gastrulation, the research clarifies evolutionary conservation and divergence in deuterostome axis patterning, offering a comparative framework for developmental and translational biology.

• HyperFluor™ 488 Antibody: Illuminating FXR LLPS and Advanced

  2026-07-10

  Explore how the HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody, an Alexa Fluor 488 conjugated secondary antibody from APExBIO, enables unprecedented clarity in visualizing FXR-driven liquid–liquid phase separation. This article uniquely bridges mechanistic cell biology with practical assay optimization for cutting-edge virology and cell imaging workflows.

• In Vitro Drug Response Evaluation: Advances and Implications

  2026-07-09

  Schwartz's dissertation introduces a nuanced framework for evaluating anti-cancer drug responses in vitro, distinguishing between proliferative arrest and cell death through dual-metric approaches. These innovations clarify drug mechanism assessment and have practical implications for the design and interpretation of DNA replication and topoisomerase II inhibition assays.

• BHPF Inhibits GPER1: New Mechanism in Neuroblastoma Apoptosi

  2026-07-09

  This study reveals that fluorene-9-bisphenol (BHPF), a BPA substitute, acts as a novel inhibitor of the G protein-coupled estrogen receptor 1 (GPER1) in human neuroblastoma cells. By integrating molecular dynamics, site-directed mutagenesis, and cell-based assays, the research uncovers BHPF's unique binding mode and antagonistic action, informing future health risk assessments of environmental bisphenols and providing a framework for dissecting GPER-mediated pathways.

• RG108: Transforming Epigenetic Modulation in Translational O

  2026-07-08

  This thought-leadership article explores how RG108, a potent DNA methyltransferase inhibitor, is redefining epigenetic research and experimental strategy in translational oncology. By integrating mechanistic insights, benchmarking, and actionable guidance, we reveal how RG108 empowers researchers to reactivate silenced tumor suppressor genes, optimize assay outcomes, and bridge preclinical discovery with future clinical impact. We draw on recent literature and comprehensive reviews to underscore the importance of precise epigenetic modulation and position RG108 as a cornerstone for next-generation cancer research.

• Acetoacetic Acid Sodium Salt in Energy Metabolism Research

  2026-07-08

  Acetoacetic acid sodium salt empowers high-sensitivity metabolic assays, offering reproducibility and translational value for diabetes and fatty acid catabolism studies. This guide delivers actionable protocols, troubleshooting tips, and workflow enhancements—bridging bench research and clinical insight.

• Selective Nanomolar IRAP Inhibitors from α-Hydroxy-β-Amino A

  2026-07-07

  The referenced study introduces a stereoselective synthetic route to α-hydroxy-β-amino acid derivatives of bestatin, yielding highly selective, nanomolar inhibitors of insulin-regulated aminopeptidase (IRAP). This work advances chemical probe design for M1 aminopeptidases, providing both methodological innovation and mechanistic insight for applications in immunology and drug discovery.

15069 records 1/1005 page Next 12345 下5页 Last page